Valsamo Anagnostou

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Neoplasms 72%
3. Immunotherapy 49%
4. Mutation 47%
5. Circulating Tumor DNA 44%
6. Lung Neoplasms 35%
7. T-Lymphocytes 30%
8. Tumor Burden 29%
9. Nivolumab 29%
10. Survival 24%
11. Biomarkers 23%
12. Cell-Free Nucleic Acids 20%
13. Breast Neoplasms 19%
14. Therapeutics 19%
15. Liquid Biopsy 18%
16. Adenocarcinoma 18%
17. ErbB Receptors 17%
18. durvalumab 17%
19. HLA Antigens 17%
20. Tumor-Infiltrating Lymphocytes 16%
21. Melanoma 16%
22. Proteins 16%
23. Ipilimumab 15%
24. Antibodies 14%
25. Cold Ischemia 14%
26. Ligands 13%
27. Mesothelioma 12%
28. Neoplasm Metastasis 12%
29. Adenocarcinoma of Lung 12%
30. Genome 12%
31. Oncogenes 11%
32. Clinical Trials 11%
33. Platinum 11%
34. Fluorescent Antibody Technique 11%
35. Drug Therapy 11%
36. Interferons 10%
37. Estrogen Receptors 10%
38. Exome 10%
39. Thyroid Nuclear Factor 1 9%
40. Colorectal Neoplasms 9%
41. Machine Learning 9%
42. Progression-Free Survival 9%
43. Phosphopyruvate Hydratase 9%
44. Immunohistochemistry 9%
45. Pemetrexed 8%
46. Histology 8%
47. Tyrosine 3-Monooxygenase 8%
48. Lung 8%
49. Tumor Biomarkers 8%
50. Residual Neoplasm 8%